TCI Wealth Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

TCI Wealth Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-191	Closed	-$20.8K	–	2502
2023 Q1	$20.8K	Hold	191	–	–	﹤0.01%	683
2022 Q4	$21.7K	Buy	191 +108	+130%	+$8.97K	﹤0.01%	662
2022 Q3	$5K	Buy	83 +5	+6%	+$349	﹤0.01%	1551
2022 Q2	$6K	Sell	78 -61	-44%	-$5.78K	﹤0.01%	1435
2022 Q1	$14K	Sell	139 -93	-40%	-$9.06K	﹤0.01%	910
2021 Q4	$25K	Hold	232	–	–	﹤0.01%	621
2021 Q3	$25K	Buy	232 +83	+56%	+$8.62K	﹤0.01%	606
2021 Q2	$14K	Buy	149 +19	+15%	+$1.75K	﹤0.01%	774
2021 Q1	$12K	Buy	130 +52	+67%	+$4.39K	0.01%	790
2020 Q4	$6K	Hold	78	–	–	﹤0.01%	839
2020 Q3	$6K	Hold	78	–	–	﹤0.01%	744
2020 Q2	$4K	Hold	78	–	–	﹤0.01%	858
2020 Q1	$2K	Buy	+78	New	+$2.64K	﹤0.01%	1159

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCI Wealth Advisors's HZNP Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 191 shares — an estimated $20.8K sold.

TCI Wealth Advisors first reported a position in HZNP in Q1 2020 and held it in 13 quarters. The position peaked at $25K in Q4 2021. 519 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

TCI Wealth Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 191 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $20.8K.
TCI Wealth Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2020 and held it in 13 quarters.
TCI Wealth Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $25K in Q4 2021.
519 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.